Updated: 27 October 2026 la 00:12. Articolul a fost revizuit pentru a reflecta informațiile disponibile la această dată.
High cholesterol is one of the most important modifiable cardiovascular risk factors, precisely because it usually causes no symptoms. A person can have high LDL levels for years without noticing anything unusual, while atherosclerotic plaques gradually form in artery walls. Blood tests therefore matter before chest pain, a heart attack or a stroke occurs—not only after an event.
But a result reading “total cholesterol 230” is not a complete diagnosis. LDL, HDL, triglycerides, non-HDL, lipoprotein(a) and, in some cases, ApoB provide different information. LDL targets also differ between a young adult with no other risk factors and someone who has already had a heart attack. This guide explains each marker, European treatment thresholds, and the updated ESC/EAS 2025 and AHA/ACC 2026 recommendations.
InfoBuz, editorial review: 26 October 2026. This article is for information only; it is not an individual interpretation of test results or a prescription. Discuss treatment, extreme values or worrying symptoms with a doctor. Medical guidelines are adapted to clinical risk and individual circumstances.
What is cholesterol and why does the body need it?
Cholesterol is a lipid essential to cell membranes and to the production of certain hormones and bile acids. The body synthesises it, mainly in the liver, and also obtains it from food. Because lipids do not circulate freely in blood plasma, they are carried in particles called lipoproteins. The issue is not cholesterol’s mere presence, but the concentration of—and duration of arterial exposure to—certain particles that can promote atherosclerosis.
LDL-C refers to the amount of cholesterol carried by low-density lipoproteins. The modern understanding of atherosclerotic disease assigns a causal role to LDL particles in the build-up of cholesterol in artery walls. This explains why lowering LDL in eligible people reduces the risk of cardiovascular events. The European Society of Cardiology, in its analysis of the 2025 update, confirms the importance of LDL and overall risk assessment.
LDL, HDL and triglycerides: what does each test measure?
| Marker | What it represents | Key point |
|---|---|---|
| Total cholesterol | Cholesterol carried by several lipoprotein fractions | Useful for screening, but insufficient on its own |
| LDL-C | Cholesterol carried by atherogenic LDL particles | The main treatment target for reducing cardiovascular risk |
| HDL-C | Cholesterol carried by HDL particles | A low level can signal risk; artificially increasing it does not guarantee fewer heart attacks |
| Triglycerides | An important form of circulating fat | High levels may have metabolic causes; extreme levels raise the risk of pancreatitis |
| Non-HDL-C | Total cholesterol minus HDL-C | Includes cholesterol in several atherogenic particles |
| ApoB | A protein present on the main atherogenic lipoprotein particles | Can help estimate their number in selected situations |
| Lp(a) | A particle largely determined by genetics | May add to risk; measuring it at least once in adulthood is useful |
LDL: why it is called “bad cholesterol” and where that description falls short
The phrase is a simplification, but a useful one for the public: cumulative exposure to high LDL promotes atherosclerotic deposits. Both the level and the number of years for which arteries are exposed matter. Someone with a genetic predisposition may have very high LDL from a young age, with risk accumulating before any symptoms appear. Not everyone with the same result has the same risk: diabetes, smoking, high blood pressure, kidney disease, family history and previous cardiovascular events all change the interpretation.
HDL: it is not an antidote that cancels out LDL
HDL particles are involved in cholesterol transport and metabolism, and low levels are statistically associated with higher cardiovascular risk. But simply raising HDL with medication has not automatically been shown to provide protection equivalent to lowering LDL. A favourable HDL result does not neutralise very high LDL. Doctors therefore interpret the lipid profile and overall risk, rather than relying on a simplistic division between “good” and “bad” cholesterol.
Triglycerides: when the issue is cardiovascular risk and when it is pancreatitis
Triglycerides can rise with excessive alcohol use, uncontrolled diabetes, certain medicines, a high-energy diet, hypothyroidism or genetic disorders. In general, fasting values above around 150 mg/dL may justify investigating the cause, although thresholds also depend on the protocol. At 500 mg/dL or above, a clinician promptly assesses secondary causes and measures to reduce the risk of pancreatitis; much higher levels raise further concern. Do not self-medicate with high doses of supplements. The ADA Standards of Care 2026 discuss the 500 mg/dL threshold and the measures required.
Which LDL levels do doctors aim for? Targets depend on cardiovascular risk
The 2019 ESC/EAS guideline, updated in 2025, does not set a single “normal LDL” level for every adult. It uses cardiovascular risk categories, with more stringent targets for people at higher risk. After a heart attack, for example, an LDL target well below 100 mg/dL may be essential; for an adult without known cardiovascular disease, the decision to start treatment depends on long-term risk and other clinical factors. The official ESC table sets out the targets in detail.
| Cardiovascular risk category | Indicative ESC/EAS LDL-C target | Note |
|---|---|---|
| Low risk | below 116 mg/dL (below 3.0 mmol/L) | May be considered |
| Moderate risk | below 100 mg/dL (below 2.6 mmol/L) | Considered in the clinical assessment |
| High risk | below 70 mg/dL (below 1.8 mmol/L) | Usually alongside a reduction of at least 50% from baseline |
| Very high risk | below 55 mg/dL (below 1.4 mmol/L) | Usually alongside a reduction of at least 50% from baseline |
These are treatment targets, not thresholds readers can use to diagnose themselves or determine their own treatment. People who have had a heart attack or an atherosclerotic ischaemic stroke, those with documented arterial disease, or those with certain combinations of diabetes and other risk factors may require assessment for very high risk. Doctors apply the guideline definitions and consider age, comorbidities and treatment tolerance—not merely the number on one test.
What is SCORE2, and why does Romania need proper risk assessment?
SCORE2 is a European tool for estimating the risk of fatal and non-fatal cardiovascular events over the next 10 years in apparently healthy people in certain age groups. SCORE2-OP is available for older adults. The model takes account of age, sex, smoking, blood pressure and lipids, with regional adaptation. It is not applied mechanically to patients with already diagnosed atherosclerotic cardiovascular disease, diabetes, kidney disease or certain genetic disorders, for whom other clinical criteria are used.
The ESC/EAS 2025 update recommends SCORE2 and SCORE2-OP for appropriate groups, as well as the inclusion of risk modifiers such as a family history of premature cardiovascular disease, certain inflammatory conditions and raised Lp(a). If an assessment is close to a decision threshold, a doctor may also consider imaging tests such as coronary artery calcium (CAC) scoring in selected circumstances. It is not automatically recommended for every symptom-free patient.
For further context, see Blood tests marked in red: why a result outside the reference range does not automatically mean disease, an article that explores an issue directly related to this topic.
What Lp(a) and ApoB tests add in 2026
Lipoprotein(a): risk strongly influenced by genetic inheritance
Lp(a) levels are largely genetically determined and do not change with diet in the same way as triglycerides. ESC/EAS 2025 regards more than 50 mg/dL (approximately 105 nmol/L) as a factor that may increase cardiovascular risk. European recommendations support considering measurement at least once during adult life, especially where there is a family history or unclear intermediate risk. Note that mg/dL and nmol/L do not have a universally exact conversion because methods and particle size differ. The full ESC/EAS update describes these particularities.
ApoB: when the cholesterol being carried does not tell the whole story
ApoB is a protein present as one copy on several types of atherogenic particle. In some metabolic profiles, particularly when triglycerides are elevated, LDL-C concentration may not perfectly reflect the number of atherogenic particles; in those circumstances, ApoB testing can complement the assessment. The 2026 AHA/ACC guideline supports selective use of ApoB, alongside Lp(a) testing at least once in a lifetime. That does not mean everyone needs every test at each check-up.
Does high cholesterol cause symptoms? Why not to wait for chest pain
In most cases, hypercholesterolaemia causes no specific pain, dizziness or fatigue. Blood tests are the usual way it is detected. In rare cases of severe genetic disorders, visible cholesterol deposits may occur in tissues, but their absence does not rule out the condition. The NHS notes that the condition is often asymptomatic.
Symptoms such as chest pressure, marked breathlessness, sudden weakness on one side of the body or speech disturbance may indicate a cardiovascular or neurological emergency, rather than an ordinary “cholesterol symptom”. If they occur suddenly, call emergency services; do not try to explain them away with an old test result.
Why LDL rises: genetics, diet and medical causes
- Genetic factors can lead to very high LDL from a young age; familial hypercholesterolaemia requires assessment and sometimes testing of relatives.
- Saturated and trans fats in some foods can affect LDL; long-term dietary quality matters more than arbitrarily cutting out one food.
- Hypothyroidism, nephrotic syndrome, some liver diseases and certain medicines can alter the lipid profile.
- Diabetes and insulin resistance can raise triglycerides and alter the characteristics of atherogenic particles.
- Smoking, high blood pressure and physical inactivity increase cardiovascular risk, even if they do not all raise the values on the same test.
- Excess alcohol can particularly raise triglycerides and carries additional risks.
For this reason, when a lipid profile is abnormal, a doctor may check blood pressure, blood glucose or HbA1c, thyroid function, family history, medication and cardiovascular history. The NICE clinical guideline recommends investigating relevant secondary causes before specialist referrals. Interpreting results solely by the red-highlighted reference ranges on a lab report can miss the clinical context.
What you can change in your diet without extreme diets
Heart-healthy dietary patterns emphasise vegetables, whole fruits, whole grains, legumes, nuts in appropriate amounts and sources of unsaturated fats. Replacing some saturated fat with vegetable oils and foods rich in soluble fibre can help lower LDL. The optimal amount and any restrictions should be adapted to allergies and medical conditions; for instance, the diet of a patient with kidney disease may require different advice.
One practical example is to change meals gradually: instead of a breakfast made entirely of pastries and processed meats, try oats, suitable yoghurt and fruit; at lunch, a serving of beans, lentils or fish with vegetables; and at dinner, a meal lower in saturated fat. The aim is not a perfect diet for three days, but a pattern that can be sustained over time. For principles of reading ingredient lists, see the InfoBuz guide to recognising ultra-processed foods.
Exercise, smoking and sleep: factors supplements cannot replace
Regular physical activity can improve metabolic profile, blood pressure and cardiovascular health. It may chiefly affect triglycerides, HDL and fitness, without on its own lowering LDL enough for someone at very high risk. Quitting smoking brings major cardiovascular benefits even if LDL does not immediately decline. Sleep and stress management complement prevention, but they do not replace treatment when treatment is indicated.
Supplements marketed for “clean cholesterol” should not be regarded as automatically equivalent alternatives to medicines tested in clinical trials. ESC/EAS 2025 stressed that a reduction in cardiovascular risk cannot be assumed merely because a supplement changes a laboratory value. Some products may contain contaminants, interact with medicines or include pharmacologically active substances. Tell your doctor about everything you take, including “natural” products.
Statins, ezetimibe and newer therapies: how treatment is decided
For people whose risk warrants medication, statins generally remain the first-line treatment for lowering LDL and the risk of cardiovascular events. If the target is not reached, a doctor may assess adding ezetimibe, PCSK9 inhibitors or other therapies, depending on risk, effectiveness, availability and tolerance. The European 2025 update includes new recommendations for bempedoic acid in certain situations, including statin intolerance.
Muscle pain and other possible side effects should be discussed with a doctor, rather than addressed by permanently stopping treatment on your own. Sometimes the dose or molecule can be changed, and symptoms may have another cause. In secondary prevention after a heart attack or atherosclerotic ischaemic stroke, unjustified discontinuation of therapy can have important consequences. Treatment should not be decided on the basis of a single online message.
Three illustrative examples: the same LDL level can mean different things
| Hypothetical situation | LDL result | Main clinical question |
|---|---|---|
| Young adult, no known disease, non-smoker | 125 mg/dL | What is the overall risk and family history? |
| Adult with high blood pressure, who smokes and has diabetes | 125 mg/dL | Is the person at high or very high risk, and which target applies? |
| Person after a heart attack, receiving treatment | 80 mg/dL | Is LDL still above the target set for secondary prevention? |
These examples do not recommend treatment in each case; they illustrate why a figure of 125 mg/dL should not be interpreted in the same way for everyone. For a patient who has had a heart attack, an LDL level of 80 mg/dL may be above the relevant target, while an adult at low risk needs to be assessed in context. Age, blood pressure, smoking history, chronic disease and family information can all change the decision.
Frequently asked questions about high cholesterol
Is a total cholesterol level of 220 mg/dL automatically dangerous?
No. It cannot be fully interpreted in isolation. LDL, HDL, triglycerides, cardiovascular health and other risk factors must be considered. On its own, it is not a prescription.
Can I have very high cholesterol without any symptoms?
Yes. Hypercholesterolaemia is often asymptomatic, and atherosclerotic deposits can develop over years. Blood tests and risk assessment are important.
Does high HDL protect me even if my LDL is high?
There is no automatic compensation. High LDL can continue to contribute to atherosclerosis, regardless of an apparently favourable HDL value.
Do I need to fast for a lipid profile?
In many situations, samples can be taken without fasting, but a doctor or laboratory may recommend a fasting sample, especially when triglycerides are very high or a specific assessment is needed. Follow the instructions you are given.
Should Lp(a) be repeated at every check-up?
Usually not. Its level is largely genetic, and guidelines recommend considering at least one measurement in adulthood. Repeating it makes sense in particular clinical situations determined by a doctor.
If I take a statin and my LDL is normal, can I stop the medicine?
Not without consulting a doctor. A good value may be the result of treatment itself. Stopping may allow LDL to rise again, and cardiovascular risk still needs to be assessed.
Conclusion: cholesterol is not treated from a table alone
High cholesterol should be addressed before it causes symptoms. LDL is central to atherosclerotic risk, but interpretation of a lipid profile depends on overall cardiovascular risk, family history, diabetes, smoking, blood pressure and any existing conditions. European and US guidelines from 2025–2026 recommend more intensive treatment for higher risk and judicious use of additional tests, rather than one target for everyone. After an unexpected result, the best next step is an informed medical assessment—not a miracle solution.
Clinical sources and guidelines
- ESC/EAS – 2025 update to the dyslipidaemia guideline.
- European Atherosclerosis Society – summary of recommendations and SCORE2.
- American Heart Association / ACC – 2026 dyslipidaemia guideline.
- ESC – LDL targets by risk category.
- NHS – high cholesterol and the absence of symptoms.
- NICE NG238 – risk assessment and secondary causes.










Discuția cititorilor
Ai o opinie sau o întrebare despre acest articol? Spune-ne ce crezi.
Fii primul care deschide discuția.
Te rugăm să păstrezi un limbaj civilizat și să discuți la subiect. Comentariile spam sunt filtrate automat.